RU95117338A - DIAGNOSTIC METHOD FOR EARLY AND INVASIVE ONCOPATOLOGY IN A SPECIFIC ONCOLOGICAL PATIENT - Google Patents
DIAGNOSTIC METHOD FOR EARLY AND INVASIVE ONCOPATOLOGY IN A SPECIFIC ONCOLOGICAL PATIENTInfo
- Publication number
- RU95117338A RU95117338A RU95117338/14A RU95117338A RU95117338A RU 95117338 A RU95117338 A RU 95117338A RU 95117338/14 A RU95117338/14 A RU 95117338/14A RU 95117338 A RU95117338 A RU 95117338A RU 95117338 A RU95117338 A RU 95117338A
- Authority
- RU
- Russia
- Prior art keywords
- blood
- weight
- formula
- percentage
- esr
- Prior art date
Links
- 238000002405 diagnostic procedure Methods 0.000 title 1
- 230000000771 oncological Effects 0.000 title 1
- 210000004369 Blood Anatomy 0.000 claims 17
- 239000008280 blood Substances 0.000 claims 17
- 210000000265 Leukocytes Anatomy 0.000 claims 6
- 101710006969 PCM5 Proteins 0.000 claims 5
- 210000001772 Blood Platelets Anatomy 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 210000002865 immune cell Anatomy 0.000 claims 4
- 210000003743 Erythrocytes Anatomy 0.000 claims 3
- 102000001554 Hemoglobins Human genes 0.000 claims 3
- 108010054147 Hemoglobins Proteins 0.000 claims 3
- 210000001616 Monocytes Anatomy 0.000 claims 3
- 238000004062 sedimentation Methods 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 210000003979 Eosinophils Anatomy 0.000 claims 2
- 102100015239 F2 Human genes 0.000 claims 2
- 210000004698 Lymphocytes Anatomy 0.000 claims 2
- 229940039716 Prothrombin Drugs 0.000 claims 2
- 108010094028 Prothrombin Proteins 0.000 claims 2
- 239000005844 Thymol Substances 0.000 claims 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 229960000790 thymol Drugs 0.000 claims 2
- 229930007823 thymol Natural products 0.000 claims 2
- 210000000601 Blood Cells Anatomy 0.000 claims 1
- 101700010927 CALM3 Proteins 0.000 claims 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 1
- 102100008702 MBD1 Human genes 0.000 claims 1
- 108060005894 PCM1 Proteins 0.000 claims 1
- MGSRCZKZVOBKFT-UHFFFAOYSA-N Thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
Claims (1)
ИК15 = СОЭ•Тр/(Hb•ЦП);
ИКБ2 = Г•ПИ/(10•ОБ),
ИКП5 = Hb•Бел•ОБ(Э + 1)•ПИ/СОЭ•100000);
ИКМ7 = (СОЭ + С + П + Ю)/(ПИ + Л); ИКМ8 + (ПИ + Hb + Л)/Тр;
ИКМ9 + ИКМ7/(ИКМ8 + 1),
где СОЭ - скорость оседания эритроцитов крови, мм/час;
Тр - количество тромбоцитов в крови (•109/л),
Нb - содержание гемоглобина в крови, г/л;
ЦП - цветной показатель крови, Г - уровень глюкозы в венозной крови, ммоль/л;
ПИ - протромбиновый индекс крови, %;
ОБ - концентрация общего билирубина в крови, мкмоль/л;
Бел - содержание общего белка в крови, г/л;
Э - процентное содержание эозинофилов в формуле крови;
С - процентное содержание сегментоядерных лейкоцитов в формуле крови;
П - процентное содержание палочкоядерных лейкоцитов в формуле крови;
Ю - процентное содержание юных лейкоцитов в формуле крови;
Л - процентное содержание лимфоцитов в формуле крови
и при отсутствии или наличии одного положительного диагностического индекса или значений показателей содержания гемоглобина, тромбоцитов и скорости оседания эритроцитов относительно порогового уровня диагностируют инвазивный рак, а при наличии двух и более положительных показателей дополнительно определяют средний диаметр опухоли, вес больного, содержание моноцитов в крови и тимоловую пробу (ед), рассчитывают диагностические индексы по формулам ИКП4 = ЦП•С•Тр•ПИ•Д/((М + 1)•Л•1000), ИКМ1 = (Тим + 1)•Д•Тр/(ПИ•Hb), ИКМ3 = Д•Тр/Вес, ИКМ5 = D•Тр/ПИ, ИКМ10 = D•(СОЭ + Тр)/(ПИ + Hb + Вес),
где D - средний диаметр опухоли, М - процентное содержание моноцитов в формуле крови; Тим - тимоловая проба (ед),
Вес - вес обследуемого пациента (кг), и при отсутствии положительных значений диагностических индексов и показателя среднего диаметра опухоли относительно порогового уровня диагностируют инвазивный рак, а при наличии одного и более положительного теста дополнительно определяют общую численность популяции всех лейкоцитов в крови (Lтот), тромбоцитов (Тртот), эритроцитов (Эртот), сегментоядерных лейкоцитов (Стот), лимфоцитов (Лтот) и моноцитов (Мтот), а также объем циркулирующей крови (ОЦК) для мужчин, равный Вес•0,07, для женщин Вес•0,065, рассчитывают общую популяцию для данных клеток крови по формуле Nабс•ОЦК6 где Nабс-абсолютное число L,Тр,Эр,С, Л и М в крови (•109/л), после чего рассчитывают показатели соотношения Вес, Lтот, Тртот, Эртот, Стот, Лтот и Мтот на средний диаметр опухоли (D) и при отсутствии положительных показателей относительно порогового уровня диагностируют инвазивный рак, а при наличии одного и более положительных показателей - раннюю онкопатологию.A method for the diagnosis of early and invasive oncopathology in a particular cancer patient by examining the patient's peripheral blood, characterized in that it determines the content of platelets, eosinophils, segmented, stab and other leukocytes, hemoglobin, total protein, glucose level, total bilirubin concentration, erythro sedimentation rate , color indicator and prothrombin blood index, calculate diagnostic indices using the formulas:
IK15 = ESR • Tr / (Hb • CPU);
IKB2 = G • PI / (10 • AB),
ICP5 = Hb • Bel • OB (E + 1) • PI / ESR • 100000);
PCM7 = (ESR + C + P + S) / (PI + L); PCM8 + (PI + Hb + L) / Tr;
PCM9 + PCM7 / (PCM8 + 1),
where ESR is the erythrocyte sedimentation rate, mm / hour;
Tr - the number of platelets in the blood (• 10 9 / l),
Нb - hemoglobin content in the blood, g / l;
CP - color indicator of blood, G - glucose level in venous blood, mmol / l;
PI - prothrombin blood index,%;
ABOUT - the concentration of total bilirubin in the blood, µmol / l;
Bel - total protein in the blood, g / l;
E is the percentage of eosinophils in the blood formula;
C is the percentage of segmented white blood cells in the blood formula;
P - the percentage of stab leukocytes in the blood formula;
S - the percentage of young white blood cells in the blood formula;
L - percentage of lymphocytes in the blood formula
and in the absence or presence of one positive diagnostic index or values of hemoglobin, platelet count and erythrocyte sedimentation rate relative to the threshold level, invasive cancer is diagnosed, and in the presence of two or more positive indicators, the average tumor diameter, patient weight, blood monocyte content and thymol are additionally determined sample (unit), diagnostic indices are calculated using the formulas IKP4 = CPU • C • Tr • PI • D / ((M + 1) • L • 1000), PCM1 = (Tim + 1) • D • Tr / (PI • Hb ), PCM3 = D • Tr / Weight, PCM5 = D • Tr / PI , PCM10 = D • (ESR + Tr) / (PI + Hb + Weight),
where D is the average diameter of the tumor, M is the percentage of monocytes in the blood formula; Tim - thymol test (unit),
Weight is the weight of the examined patient (kg), and in the absence of positive values of the diagnostic indices and the average tumor diameter relative to the threshold level, invasive cancer is diagnosed, and in the presence of one or more positive tests, the total population of all white blood cells in the blood (Lot), platelets is additionally determined (Trotot), erythrocytes (Ertot), segmented white blood cells (Stot), lymphocytes (Ltot) and monocytes (Mtot), as well as the circulating blood volume (BCC) for men, equal to Weight • 0.07, for women Weight • 0.065, calculated The total population for these blood cells is calculated according to the formula Nabs • BCC6 where Nabs is the absolute number of L, Tr, Er, C, L and M in the blood (• 10 9 / l), after which the ratio Weight, Ltot, Trtot, Ertot is calculated , Stot, Ltot and Mtot on the average tumor diameter (D) and in the absence of positive indicators relative to the threshold level, invasive cancer is diagnosed, and in the presence of one or more positive indicators - early oncopathology.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU95117338A RU2133466C1 (en) | 1995-10-06 | 1995-10-06 | Method for diagnosing oncological pathological cases, in particular, oncological patient at early stage and in noninvasive mode |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU95117338A RU2133466C1 (en) | 1995-10-06 | 1995-10-06 | Method for diagnosing oncological pathological cases, in particular, oncological patient at early stage and in noninvasive mode |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU95117338A true RU95117338A (en) | 1997-10-10 |
| RU2133466C1 RU2133466C1 (en) | 1999-07-20 |
Family
ID=20172748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU95117338A RU2133466C1 (en) | 1995-10-06 | 1995-10-06 | Method for diagnosing oncological pathological cases, in particular, oncological patient at early stage and in noninvasive mode |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2133466C1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2593015C1 (en) * | 2015-06-10 | 2016-07-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия" Министерства Здравоохранения Российской Федерации (ГБОУ ВПО НижГМА Минздрава России) | Differential diagnostic technique for diseases with oncological and non-oncological genesis |
-
1995
- 1995-10-06 RU RU95117338A patent/RU2133466C1/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Spaet et al. | Defective platelets in essential thrombocythemia | |
| Rackoff et al. | Pulse oximetry and factors associated with hemoglobin oxygen desaturation in children with sickle cell disease | |
| Egli et al. | Effect of progressive haemodilution with hydroxyethyl starch, gelatin and albumin on blood coagulation | |
| HAM | Studies on destruction of red blood cells: I. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: an investigation of the mechanism of hemolysis, with observations on five cases | |
| Fox et al. | Dirunal variations in rabbits: hematological parameters | |
| Kenny et al. | Erythrocyte deformability in sickle‐cell crisis | |
| Saxena et al. | Red blood cell distribution width in untreated pernicious anemia | |
| Ramírez et al. | Morphological features of red blood cells in subjects with sickle cell trait: changes during exercise | |
| Sié et al. | D-dimer levels in patients with long-term antecedents of deep venous thrombosis | |
| RU95117338A (en) | DIAGNOSTIC METHOD FOR EARLY AND INVASIVE ONCOPATOLOGY IN A SPECIFIC ONCOLOGICAL PATIENT | |
| RU95118236A (en) | METHOD FOR DIAGNOSTIC OF REMOTE METASTASES OF MALIGNANT NEW FORMATIONS IN ONCOLOGICAL PATIENT | |
| RU2328741C1 (en) | Method of erythrocytes osmoresistivity evaluation | |
| Mizock et al. | Confirmation of spurious hypoxemia using continuous blood gas analysis in a patient with chronic myelogenous leukemia | |
| BERGQVIST et al. | Juvenile diabetes mellitus—a risk factor for postoperative venous thromboembolism? | |
| RU95117904A (en) | METHOD FOR DIAGNOSTIC OF GENERALIZATION OF MALIGNANT NOVO-FORMATIONS IN ONCOLOGIC PATIENTS | |
| Biesiada et al. | Rheological properties of erythrocytes in patients suffering from erysipelas. Examination with LORCA device | |
| RU2133466C1 (en) | Method for diagnosing oncological pathological cases, in particular, oncological patient at early stage and in noninvasive mode | |
| RU2132059C1 (en) | Method for diagnosing malignant neoplasm generalization in oncological patients | |
| RU95116510A (en) | METHOD FOR DIAGNOSTIC OF METASTASES OF MALIGNANT NEW FORMATIONS IN REGIONAL LYMPHATIC NODES | |
| RU2131606C1 (en) | Method for diagnosing malignant neoplasm metastases in regional lymphatic nodes | |
| RU2195652C2 (en) | Method of diagnosing endogenous intoxication in case of severe trauma | |
| Easa | Coagulation abnormalities associated with localized hemorrhage in the neonate | |
| RU2187113C2 (en) | Method for predicting purulent-septic complications in patients during acute period of polytrauma | |
| Alonsozana et al. | In vitro interference of the red cell substitute pyridoxalated hemoglobin-polyoxyethylene with blood compatibility, coagulation, and clinical chemistry testing | |
| RU2232988C2 (en) | Method for estimation of content of blood leukocytes, erythrocytes and platelets taking into account heme concentration |